Off-label immunotherapy prescription: Financial implications for payers and patients.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.8_suppl.6
Abstract: 6Background: Pembrolizumab (PEM) and nivolumab (NIV) are FDA-approved immunotherapy agents for specific indications. These drugs are extremely costly to the health care system, payers, and ultimately, patients, and little is known about their utilization for… read more here.
Keywords: prescription financial; label immunotherapy; immunotherapy prescription; oncology ... See more keywords